Differences in cytochrome P450 forms involved in the metabolism of N,N-Dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl]ethylamine monohydrochloride (NE-100), a novel sigma ligand, in human liver and intestine

Drug Metabolism and Disposition

Volumn 31, Issue 1, 2003, Pages 60-66

  Yamamoto, Takahito ^a   Hagima, Naoko ^a   Nakamura, Masato ^a   Kohno, Yoshiro ^a   Nagata, Kiyoshi ^b   Yamazoe, Yasushi ^b  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 METHOXY 3 (2 PHENYLETHOXY)PHENYL] N,N DIPROPYLETHYLAMINE; 7 ETHOXY 4 TRIFLUOROMETHYLCOUMARIN; CARBON 14; CHLORZOXAZONE; COUMARIN DERIVATIVE; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DEXTROMETHORPHAN; DEXTRORPHAN; ENZYME ANTIBODY; KETOCONAZOLE; LANSOPRAZOLE; MONOCLONAL ANTIBODY; OMEPRAZOLE DERIVATIVE; PARACETAMOL; PROADIFEN; RECOMBINANT ENZYME; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TESTOSTERONE; UMBELLIFERONE; UNCLASSIFIED DRUG;

ARTICLE; DRUG BIOAVAILABILITY; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME SUBSTRATE; HUMAN; HUMAN TISSUE; INTESTINE; KINETICS; LIVER MICROSOME; MENTAL DISEASE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA;

ANISOLES; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; INTESTINES; ISOENZYMES; LIGANDS; LIVER; MICROSOMES, LIVER; PROPYLAMINES; RECEPTORS, SIGMA;

EID: 0038685784     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.31.1.60     Document Type: Article

References (40)

1. Andersson T, Langerstrom PO, Miners JO, Verines ME, Weldolf L, and Birkett DJ (1993) High performance liquid chromatographic assay for human liver microsomal omeprazole metabolism. J Chromatogr 619:291-297.
2. Anttila S, Vainio H, Hietanen E, Camus AM, Malaveille C, Brun G, Husgafvel-Pursiainen K, Heikkila L, Karjalainen A, and Bartsch H (1992) Immunohistochemical detection of pulmonary cytochrome P450IA and metabolic activities associated with P450IA1 and P450IA2 isozymes in lung cancer patients, Environ Health Perspect 98:179-182.
3. Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE, and Chenery RJ (1995) Ketoconazole and sulfaphenazole as the respective selective inhibitors of p4503A and 2C9. Xenobiotica 25:261-270.
4. Beischlag TV, Kalow W, Mahon WA, and Inaba T (1992) Diazepam metabolism by rat and human liver in vitro: inhibition by mephenytoin. Xenobiotica 22:559-567.
5. Chaki S, Okuyama S, Ogawa S, Tanaka M, Muramatsu M, Nakazato A, and Tomizawa K (1996) Solubilization and characterization of binding sites for [3H]NE-100, a novel and potent sigma 1 ligand, from guinea pig brain. Life Sci 59:1331-1340.
6. Chaki S, Tanaka M, Muramatsu M, and Otomo S (1994) NE-100, a novel potent δ ligand, preferentially binds to δ 1 binding sites in guinea pig brain. Eur J Pharmacol 251:R1-R2.
7. Chang TK, Gonzalez FJ, and Waxman DJ (1994) Evaluation of triacetyloleandomycin, alphanaphtoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes p450. Arch Biochem Biophys 311:437-442.
8. Davies BI, Maesen FP, and Teengs JP (1984) Serum and sputum concentrations of enoxacin after single oral dosing in a clinical and bacteriological study. J Antipnicrob Chemother 14 (Suppl C):83-89.
9. Ducharme J, Abdullah S, and Wainer IW (1996) Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A4 activity. J Chromatogr B Biomed Appl 678:113-128.
10. Ekins S, VandenBranden M, Ring BJ, and Wrighton SA (1997) Examination of purported probes of human CYP2B6, Pharmacogenetics 7:165-179.
11. Gonzalez FI (1988) The molecular biology of cytochrome p450s. Pharmacol Rev 40:243-288.
12. Koenigs LL, Peter RM, Thompson SJ, Rettie AE, and Trager WF (1997) Mechanism-based inactivation of human liver cytochrome p450 2A6 by 8-methoxypsoralen. Drug Metab Dispos 25:1407-1415.
13. Kolars JC, Awni WM, Merion RM, and Watkins PB (1991) First-pass metabolism of cyclosporin by the gut. Lancet 338:1488-1490.
14. Kunze KL and Trager WF (1993) Isoform-selective mechanizm-based inhibition of human cytochrome p450 IA2 by furafylline. Chem Res Toxicol 6:649-656.
15. Lampen A, Christians U, Guengerich FP, Watkins PB, Kolars JC, Bader A, Gonschior AK, Dralle H, Hackbarth I, and Sewing KF (1995) Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions and interindividual variability. Drug Metab Dispos 23:1315-1324.
16. Lown KS, Kolars JC, Thummel KE, Barnett JL, Kunze KL, Wrighton SA, and Watkins PB (1994) Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab Dispos 22:947-955.
17. Lucas D, Menez JF, and Berthou F (1996) Chlorzoxazone: an in vitro and in vivo substrate probe for liver CYP2E1. Methods Enzymol 272:115-123.
18. Madani S, Paine MF, Lewis L, Thummel KE, and Shen DD (1999) Comparison of CYP2D6 content and metoprolol oxidation between microsomes isolated from human livers and small intestines. Pharm Res (NY) 16:1199-1205.
19. Mankowski DC (1999) The role of CYP2C19 in the metabolism of (+/-) bufuralol, the prototypic substrate of CYP2D6. Drug Metab Dispos 27:1024-1028.
20. Maurice M, Pichard L, Daujat M, Fabre I, Joyeux H, Domergue J, and Maurel P (1992) Effects of imidazole derivatives on cytochromes p450 from human hepatocytes in primary culture. FASEB J 6:752-758.
21. Nagata K, Gonzalez FJ, Yamazoe Y, and Kato R (1990) Purification and characterization of four catalytically active testosterone 6β-hydroxylase P-450 from rat liver microsomes: comparison of a novel form with three structuraly and functionally related forms. J Biochem 107:718-725.
22. Nelson DR, Kamataki T, Waxman DJ, Guengerich FP, Estabrook RW, Feyereisen R, Gonzalez FJ, Coon MJ, Gunsalus IC, Gotoh O, et al. (1993) The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes and nomenciature. DNA Cell Biol 12:1-51.
23. Obach RS (1997) Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine and propranolol. Drug Metab Dispos 25:1359-1369.
24. Obach RS, Zhang QY, Dunbar D, and Kaminsky LS (2001) Metabolic characterization of major human small intestinal cytochrome p450s. Drug Metab Dispos 29:347-352.
25. Okuyama S, Imagawa Y, Ogawa S, Araki H, Ajima A, Tanaka M, Muramatsu M, Nakazato A, Yamaguchi K, Yoshida S, and Otomo S (1993) NE-100, a novel sigma receptor ligand: in vivo tests. Life Sci 53:285-290.
26. Okuyama S, Imagawa Y, Sakagawa T, Nakazato A, Yamaguchi K, Katoh M, Yamada S, Araki H, and Otomo S (1994) NE-100, a novel sigma receptor ligand: effect on phencyclidine-induced behaviors in rats, dog and monkeys. Life Sci 55:133-138.
27. Olesen OV and Linnet K (2000) Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine. Br J Clin Pharmacol 50:563-571.
28. Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP, Baff DM, Gillies BS, and Thummel KE (1996) First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 60:14-24.
29. Rodrigues AD, Kukulka MJ, Surber BW, Thomas SB, Uchic JT, Rotert GA, Michel G, Thomekromer B, and Machinist JM (1994) Measurement of liver microsomal cytochrome-p450 (CYP2D6) activity using [O-methyl-C-14]dextromethorphan. Anal Biochem 219:309-320.
30. Sanwald P, Blankson EA, Dulery BD, Schoun J, Huebert ND, and Dow J (1995) Isocratic high performance liquid chromatographic method for the separation of testosterone metabolites, J Chromatogr B Biomed Appl 672:207-215.
31. Tassaneeyakul W, Birkett DJ, Veronese ME, Mcmanus ME, Tukey RH, Quattrochi LC, Gelboin HV, and Miners JO (1993) Specific of substrate and inhibitor probes for human cytochrome p450 1A1 and 1A2, J Pharmacol Exp Ther 265:401-407.
32. Venkatakrishnan K, von Moltke LL, and Greenblatt DJ (1999) Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs. J Clin Pharmacol 39:567-577.
33. Watkins PB, Wrighton SA, Schuetz EG, Molowa DT, and Guzelian PS (1987) Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Investig 80:1029-1036.
34. Wijnands WJ, Van Herwaarden CL, and Vree TB (1984) Enoxacin raises plasma theophylline concentrations. Lancet 14:108-109.
35. Wrighton SA, Campanile C, Thomas PE, Mainres SL, Watkins PB, Parker G, Mendepicon G, Haniu M, Sheively J, Levin W, and Guzelian PS (1986) Identification of a human liver cytochrome p-450 homologous to the major isosafrole-inducible cytochrome p-450 in the rat. Mol Pharmacol 29:405-410.
36. Wu CY, Benet LZ, Hebert MF, Gupta SK, Rowland M, Gomez DY, and Wacher VJ (1995) Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther 58:492-497.
37. Yamada J, Sakuma M, and Suga T (1991) Assay of fatty acid ω-hydroxylation using high performance liquid chromatography with fluorescence labeling reagent, 3-bromomethyl-7-methoxy-1, 4-benzixazin-2-one (BrMB). Anal Biochem 199:132-136.
38. Yasumori T, Chen L, Nagata K, Yamazoe Y, and Kato R (1993) Species differences in stereoselective metabolism of mephenytoin by cytochrome P450 (CYP2C and CYP3A). J Pharmacol Exp Ther 264:89-94.
39. Zeldin DC, Foley J, Goldsworthy SM, Cook ME, Boyle JE, Ma J, Moomaw CR, Tomer KB, Steenbergen C, and Wu S (1997) CYP2J subfamily cytochrome P450s in the gastrointestinal tract: expression, localization and potential functional significance. Mol Pharmacol 51:931-943.
40. Zhang QY, Dunbar D, Ostrowska A, Zeisloft S, Yang J, and Kaminsky LS (1999) Characterization of human small intestinal cytochromes P-450. Drug Metab Dispos 27:804-809.